Back

Changes in glycated hemoglobin in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan

31 August 2019 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster Session 1 - Treatment of the chronic heart failure Pharmacotherapy ESC Premium Access ESC Congress 2019

9 More presentations in this session

Presentation thumbnail
Transcoronary transfer of Wharton's jelly mesenchymal pluripotent stem cells in patients with chronic ischaemic heart failure shows safety and unprecedented high-grade myocardial uptake
Doctor A. Kozynacka (Krakow, PL)
Abstract
Presentation thumbnail
Effect of sacubitril-valsartan in reducing physical frailty in patients with advanced heart failure in waiting list for heart transplantation
Doctor G. Benincasa (Naples, IT)
Abstract Slides
Presentation thumbnail
Use of sacubitril-valsartan in an extensive long term follow up cohort in real life
Doctor A. Garcia Quintana (Palmas de Gran Canaria, Las, ES)
Abstract Slides
Presentation thumbnail
Valsartan reduces level of soluble ST2 and left ventricle remodeling in patients with dual chamber pacemaker
Mrs E. Radzik (Zabrze, PL)
Abstract
Presentation thumbnail
Eligible patients for the PARADIGM-HF trial in a real-world outpatient clinic and its cardiovascular risk
Doctor X. Chen (Chengdu, CN)
Abstract Slides

Access the full session

Session thumbnail
Poster Session 1 - Treatment of the chronic heart failure

The Event

Event poster

ESC Congress 2019

31 August - 4 September 2019

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources